How Could uniQure's (NASDAQ:QURE) FDA Priority Review Shape the Future of Huntington's Disease Treatment?

• Updated 36-month analysis of all 15 high-dose patients showed an 80% slowing on cUHDRS and 67% slowing on TFC

Sonal Goyal | 05 November 2026

What Does FDA Alignment Mean for Radiopharm Theranostics' (NASDAQ:RADX) Brain Metastases Imaging Agent RAD101?

• The trial is expected to enroll approximately 280 patients, considerably smaller than some historical registrational imaging studies.

Sonal Goyal | 05 November 2026

• The company holds $815.4 million in cash and cash equivalents as of November 3, 2026, with runway extending through the end of 2029.

Sonal Goyal | 05 November 2026

• Full-year 2026 guidance was raised to $3,500–$3,550 million in Portfolio Receipts, up from the prior range of $3,400–$3,500 million.

Sonal Goyal | 05 November 2026

• The company reiterated full-year 2026 RYTELO revenue guidance at the mid-to-high end of $220–$240 million.

Sonal Goyal | 05 November 2026

• Preliminary multiple-ascending dose data for BP-205 showed favourable safety, tolerability, and pharmacokinetic results.

Sonal Goyal | 05 November 2026

• The collaboration builds on a working relationship between MindWalk and Teva Australia that dates back to 2018

Sonal Goyal | 05 November 2026

• The stock will continue trading onNasdaqunder the symbol JSPR with a new CUSIP number.

Sonal Goyal | 05 November 2026

• Two new technology transfer projects were secured during the quarter, supporting an NDA and a marketed product.

Sonal Goyal | 05 November 2026

• The company raised its full-year 2026 constant-currency revenue growth guidance to 9%–10% and adjusted diluted EPS to $4.40–$4.50

Sonal Goyal | 05 November 2026